Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

19177 items
12:00 AM, Mar 22, 1993  |  BioCentury | Product Development

Second time not the charm; Angioplasty touted as alternative to tPA

Second time not the charm Gensia Pharmaceutical Inc.'s presentation at the American College of Cardiology meeting of Phase III data on Arasine in coronary artery bypass surgery failed to reassure investors, who pushed the stock...
12:00 AM, Mar 22, 1993  |  BioCentury | Finance

Analyst picks & changes

Amgen Inc. Dillon, Read analyst Larry Bloom upgraded Amgen Inc. to "attractive" from "neutral," saying Neupogen G-CSF sales have recovered in the past five weeks and the company is taking steps to guard against a...
12:00 AM, Mar 22, 1993  |  BioCentury | Politics, Policy & Law

Set pricing before deals

Wyden: Set pricing before deals By Steve Usdin Contributing Editor WASHINGTON - Rep. Ron Wyden has introduced legislation that would require companies to provide product-pricing formulas prior to granting of any license...
12:00 AM, Mar 22, 1993  |  BioCentury | Politics, Policy & Law

Text of the Wyden legislation

Text of the Wyden legislation Following is the text of Rep. Ron Wyden's legislation to establish price regulation over drugs and devices emanating from government-funded research. This early version is subject to revision. ...
12:00 AM, Mar 22, 1993  |  BioCentury | Politics, Policy & Law

Give a little, get a lot

Give a little, get a lot The biotechnology industry won a round in Washington last week, as the Securities and Exchange Commission adopted a policy that incorporates the substance of an industry proposal to change...
12:00 AM, Mar 22, 1993  |  BioCentury | Strategy

Politics chills business

TSIN levies blame for cutbacks TSIN levies blame for cutbacks Politics chills business TSI Corp., saying uncertainties about President Clinton's health care policies were hurting its preclinical and clinical testing businesses,...
12:00 AM, Mar 22, 1993  |  BioCentury | Strategy

Therion's course for HIV vaccine

Therion's course for HIV vaccine By Karen Bernstein Editor-in-ChiefTherion Biologics Corp. has taken up the challenge of developing a live, attenuated HIV vaccine, although the research is more likely to result in other products than...
12:00 AM, Mar 15, 1993  |  BioCentury | Strategy

Blech adjusts to new environment

Blech adjusts to new environment Intelligent consolidations are going to be one of the keys to transforming middle-tier biotech companies into top-tier companies, according to New York investor David Blech. Two companies in which Blech...
12:00 AM, Mar 15, 1993  |  BioCentury | Strategy

Alza works balance sheet magic

Alza Corp.'s spin-off of Therapeutic Discovery Corp. to its shareholders, which is structured much like an R&D partnership without the partners, could provide a model for product development funding by other biotech companies, once they...
12:00 AM, Mar 15, 1993  |  BioCentury | Regulation

Too much

Too much The Scripps-Sandoz agreement is in danger of becoming the taxol of technology transfer, held up by opponents as a representative example of purported abuse and lax regulation, when in fact it may be...

Pages